Effects of genetic ablation and pharmacological inhibition of HuR on gene expression, iron metabolism, and hormone levels.

ABSTRACT:

Background

HuR/ELAV1, a ubiquitous RNA-binding protein, belongs to the RNA-binding protein family and is crucial for stabilizing and regulating the translation of various mRNA targets, influencing gene expression. Elevated HuR levels are associated with multiple disorders, including cancer and neurodegenerative diseases. Despite the identification of small molecule inhibitors targeting HuR, their detailed characterization remains limited. Recently, Eltrombopag, an FDA-approved drug for immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, emerged as a potential HuR inhibitor. However, the specific molecular pathways influenced by both HuR and Eltrombopag are not fully understood.

Results

Our study demonstrates that Eltrombopag operates via HuR inhibition

SUBMITTER: Idlin N 

PROVIDER: S-EPMC11756078 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature